Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARγ in normal mouse skin keratinocytes

Journal of Investigative Dermatology

Volumn 123, Issue 6, 2004, Pages 1110-1119

  He, Guobin ^a   Thuillier, Philippe ^b   Fischer, Susan M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b IL   (United States)

Author keywords

Nuclear receptors; Proliferation; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CIGLITAZONE; CYCLIN D1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; KERATINOCYTE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CELL;

EID: 9744249460     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.23465.x     Document Type: Article

References (34)

1. Altiok S, Xu M, Spiegelman BM: PPARγ induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 11:1987-1998, 1997
2. Barak Y, Nelson MC, Ong ES, et al: PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585-595, 1999
3. Dotto GP, O'Connell J, Patskan G, Conti C, Ariza A, Slaga TJ: Malignant progression of papilloma-derived keratinocytes: Differential effects of the ras, neu, and p53 oncogenes. Mol Carcinog 1:171-179, 1988
4. Eligini S, Banfi C, Brambilla M, et al: 15-deoxy-delta12,14-Prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial ceils: Evidence for ERK1/2 signaling pathway blockade. Thromb Haemost 88:524-532, 2002
5. Elstner E, Muller C, Koshizuka K, et al: Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95:8806-8811, 1998
6. Fajas L, Debril MB, Auwerx J: Peroxisome proliferator-activated receptor-γ: From adipogenesis to carcinogenesis. J Mol Endocrinol 27:1-9, 2001
7. Fajas L, Egler V, Reiter R, Miard S, Lefebvre AM, Auwerx J: PPARγ controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene 22:4186-4193, 2003
8. Gardner OS, Dewar BJ, Earp HS, Samet JM, Graves LM: Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J Biol Chem 278:46261-46269, 2003
9. Gurnell M, Wentworth JM, Agostini M, et al: A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J Biol Chem 275:5754-5759, 2000
10. Huang WC, Chio CC, Chi KH, Wu HM, Lin WW: Superoxide anion-dependent Raf/MEK/ERK activation by peroxisome proliferator activated receptor γ agonists 15-deoxy-delta(12,14)-prostaglandin J(2), ciglitazone, and GW1929. Exp Cell Res 277:192-200, 2002
11. Hu E, Kim JB, Sarraf P, Spiegelman BM: Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 274:2100-2103, 1996
12. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650, 1990
13. Kim JA, Park KS, Kim HI, Oh SY, Ahn Y, Oh JW, Choi KY: Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells. Cancer Lett 179:185-195, 2002
14. Koga H, Sakisaka S, Harada M, et al: Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33:1087-1097, 2001
15. Kubota T, Koshizuka K, Williamson EA, et al: Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58:3344-3352, 1998
16. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 270:12953-12956, 1995
17. Lennon AM, Ramauge M, Dessouroux A, Pierre M: MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-Delta (12-14)- prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor γ-independent mechanisms involving reactive oxygenated species. J Biol Chem 277:29681-29685, 2002
18. Lin S, Wang W, Wilson GM, Yang X, Brewer G, Holbrook NJ, Gorospe M: Down-regulation of cyclin D1 expression by prostaglandin A(2) is mediated by enhanced cyclin D1 mRNA turnover. Mol Cell Biol 20:7903-7913, 2000
19. Martinez LA, Chen Y, Pavone A, Fischer SM, Conti CJ: Deregulated expression of cyclin D1 overrides antimitogenic signals. Oncogene 19:315-322, 2000
20. Michalik L, Desvergne B, Tan NS, et al: Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. J Cell Biol 154:799-814, 2001
21. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93:229-240, 1998
22. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res 61:6213-6218, 2001
23. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH: Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr Biol 11:764-768, 2001
24. Pignatelli M, Cortes-Canteli M, Lai C, Santos A, Perez-Castillo A: The peroxisome proliferator-activated receptor γ is an inhibitor of ErbBs activity in human breast cancer cells. J Cell Sci 114:4117-4126, 2001
25. Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S: Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells. Cancer Res 63:958-964, 2003
26. Rosen ED, Spiegelman BM: PPARα: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731-37734, 2001
27. Ruggeri B, Caamano J, Goodrow T, et al: Alterations of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res 51:6615-6621, 1991
28. Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 4:1046-1052, 1998
29. Sherr CJ: D-type cyclins. Trends Biochem Sci 20:187-190, 1995
30. Thuillier P, Anchiraico GJ, Nickel KP, et al: Activators of peroxisome proliferator-activated receptor-α partially inhibit mouse skin tumor promotion. Mol Carcinog 29:134-142, 2000
31. Tontonoz P, Singer S, Forman BM, et al: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci USA 94:237-241, 1997
32. Wang C, Fu M, D'Amico M, et al: Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor γ-dependent repression of cyclin D1. Mol Cell Biol 21:3057-3070, 2001
33. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671, 1994
34. Westergaard M, Henningsen J, Svendsen ML, et al: Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol 116:702-712, 2001